Cargando…

Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer

Triple negative breast cancer (TNBC) is the most aggressive breast cancer accounting for around 15% of identified breast cancer cases. TNBC lacks human epidermal growth factor receptor 2 (HER2) amplification, is hormone independent estrogen (ER) and progesterone receptors (PR) negative, and is not r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahman, Fatemah, Pittalà, Valeria, Haider, Mohamed, Greish, Khaled
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234460/ https://www.ncbi.nlm.nih.gov/pubmed/34204015 http://dx.doi.org/10.3390/jpm11060559

Ejemplares similares

Curcumin–Copper Complex Nanoparticles for the Management of Triple-Negative Breast Cancer
por: Greish, Khaled, et al.
Publicado: (2018)

Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity
por: Alimoradi, Houman, et al.
Publicado: (2018)

In Vivo Evaluation of Anti-Nociceptive Effects of Silver Nanoparticles
por: Morsi, Shereen, et al.
Publicado: (2022)

Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer
por: Abduh, Maisa Siddiq
Publicado: (2023)

Selective Targeting of Breast Cancer by Tafuramycin A Using SMA-Nanoassemblies
por: El-Deeb, Ibrahim M., et al.
Publicado: (2021)

The Potential Role of Sildenafil in Cancer Management through EPR Augmentation
por: Haider, Mohamed, et al.
Publicado: (2021)

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer
por: Haider, Mohamed, et al.
Publicado: (2022)

New Arylethanolimidazole Derivatives as HO-1 Inhibitors with Cytotoxicity against MCF-7 Breast Cancer Cells
por: Ciaffaglione, Valeria, et al.
Publicado: (2020)

Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
por: Tian, Jun, et al.
Publicado: (2018)

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
por: Gaule, Patricia, et al.
Publicado: (2019)

In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
por: Passos, Ioannis D, et al.
Publicado: (2023)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Nanoformulations for Delivery of Pentacyclic Triterpenoids in Anticancer Therapies
por: Kaps, Anna, et al.
Publicado: (2021)

Oral Insulin Delivery Using Poly (Styrene Co-Maleic Acid) Micelles in a Diabetic Mouse Model
por: Bahman, Fatemah, et al.
Publicado: (2020)

Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer
por: Zeng, Fan, et al.
Publicado: (2015)

Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
por: McKnight, Brooke N., et al.
Publicado: (2020)

Anticancer activity of Zingiber ottensii essential oil and its nanoformulations
por: Panyajai, Pawaret, et al.
Publicado: (2022)

Synthesis, Nanoformulations, and In Vitro Anticancer Activity of N-Substituted Side Chain Neocryptolepine Scaffolds
por: El Sayed, Ibrahim El-Tantawy, et al.
Publicado: (2022)

Targeting triple‐negative breast cancer with an aptamer‐functionalized nanoformulation: a synergistic treatment that combines photodynamic and bioreductive therapies
por: Chou, Yi-Te, et al.
Publicado: (2021)

A multivariate statistical analysis of the effects of styrene maleic acid encapsulated RL71 in a xenograft model of triple negative breast cancer
por: Martey, Orleans N.K., et al.
Publicado: (2019)

Novel Structural Insight into Inhibitors of Heme Oxygenase-1 (HO-1) by New Imidazole-Based Compounds: Biochemical and In Vitro Anticancer Activity Evaluation
por: Greish, Khaled F., et al.
Publicado: (2018)

Nanoformulation of Biogenic Cefotaxime-Conjugated-Silver Nanoparticles for Enhanced Antibacterial Efficacy Against Multidrug-Resistant Bacteria and Anticancer Studies
por: Halawani, Eman M, et al.
Publicado: (2020)

Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer
por: Martey, Orleans, et al.
Publicado: (2017)

From Far West to East: Joining the Molecular Architecture of Imidazole-like Ligands in HO-1 Complexes
por: Floresta, Giuseppe, et al.
Publicado: (2021)

Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines
por: Wong, Fu Hou, et al.
Publicado: (2022)

Nanoformulations of Ursolic Acid: A Modern Natural Anticancer Molecule
por: Wang, Longyun, et al.
Publicado: (2021)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

The Promise of Nanotechnology in Personalized Medicine
por: Alghamdi, Maha Ali, et al.
Publicado: (2022)

Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells
por: Jeon, Ye-Won, et al.
Publicado: (2022)

Novel Heme Oxygenase-1 (HO-1) Inducers Based on Dimethyl Fumarate Structure
por: Sorrenti, Valeria, et al.
Publicado: (2020)

Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release
por: Shahein, Samar A, et al.
Publicado: (2019)

Potent Small-Molecule Inhibitors Targeting Acetylated Microtubules as Anticancer Agents Against Triple-Negative Breast Cancer
por: Kwon, Ahreum, et al.
Publicado: (2020)

The “Yin and Yang” of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers
por: Varghese, Elizabeth, et al.
Publicado: (2018)

CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype
por: Filippi, Silvia, et al.
Publicado: (2022)

Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells
por: Yin, Li, et al.
Publicado: (2020)

Design Principles Governing the Development of Theranostic Anticancer Agents and Their Nanoformulations with Photoacoustic Properties
por: Kyrkou, Stavroula G., et al.
Publicado: (2022)

Heme Oxygenase Modulation Drives Ferroptosis in TNBC Cells
por: Consoli, Valeria, et al.
Publicado: (2022)

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)
por: Qian, Xiao-Long, et al.
Publicado: (2017)

Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin
por: Granit, Avital, et al.
Publicado: (2022)

The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer
por: Adinew, Getinet M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_958h5qql7i15pgr0p10mt14k31